Back to top

Analyst Blog

Zacks Equity Research

Perrigo Cleared for Generic Mucinex


 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Perrigo Company (PRGO - Analyst Report) recently announced that it has won a summary judgment in the patent case involving the generic version of Adams Respiratory Therapeutics’ drug Mucinex.  Adams Respiratory Therapeutics is a subsidiary of Reckitt Benckiser Group. Perrigo had received approval for its generic version of Mucinex in December 2011. It plans to launch the drug within the next 90 days. Mucinex indicated to relieve chest congestion has been identified as one of the important product launches for the company in fiscal 2012.

In another recent development Perrigo announced that it has signed a definitive agreement to acquire the assets of Georgia based private company CanAm Care. A distributor of diabetes care products, CanAm Care will expand Perrigo’s presence in the diabetes care market.

Our Recommendation

We currently have a Neutral recommendation on Perrigo. The stock carries a Zacks #3 Rank (short-term “Hold” rating).

We believe Perrigo has a sustainable and diversified product portfolio. Besides, Perrigo’s strong position in the brand over-the-counter (OTC) pharmaceutical market and growing generics and active pharmaceuticals ingredient (API) businesses can help it deliver solid top- and bottom-line growth in the coming years. Perrigo also has a very strong and impressive pipeline which could drive growth in fiscal 2012 and beyond.

We are, however, concerned about the competitive pressures faced by the Consumer HealthCare (CHC) segment which accounts for a majority of the company’s revenues. Moreover, the benefits that the CHC segment reaped in the last few quarters due to product recalls at rival Johnson & Johnson (JNJ - Analyst Report) may not continue in 2012 with J&J expected to be back in the market soon.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%